Abstract
Background/Aims In March-2024, the UK government announced plans to introduce a new Vaping Products Duty that will tax e-liquids based on their nicotine strength. This study examined trends in the nicotine strength of e-liquids used by adult vapers and differences in those currently used across relevant subgroups.
Design Nationally-representative, cross-sectional household survey, July-2016 to January-2024.
Setting Great Britain.
Participants 7,957 adult vapers.
Main outcome measures Participants were asked whether the e-cigarette they mainly use contains nicotine and the e-liquid strength. We used logistic regression to estimate time trends in different nicotine strengths used (no nicotine/>0-≤6/7-11/12-19/≥20 mg/ml), overall in England and stratified by main device type (disposable/refillable/pod), age (≥18y), and smoking status. We explored current differences in nicotine strength among those surveyed between January-2022 and January-2024 in Great Britain by main device type, age (≥16y), gender, occupational social grade, history of ≥1 mental health conditions, smoking status, and (among past-year smokers) level of cigarette addiction.
Results The proportion of vapers in England using high-strength (≥20mg/ml) e-liquids increased from an average of 3.8% [95%CI 2.9-5.0%] up to June-2021 to 32.5% [27.9-37.4%] in January-2024 (when 93.3% reported using exactly 20mg/ml). This rise was most pronounced among those using disposable e-cigarettes, those aged 18-24y, and all smoking statuses (including never smokers) except long-term (≥1y) ex-smokers. Of those surveyed in 2022-24 in Great Britain, overall, 89.5% [88.1-90.8%] said they usually used e-cigarettes containing nicotine, 8.7% [7.5-10.0%] used nicotine-free e-cigarettes, and 1.8% [1.2-2.4%] were unsure. The proportion using ≥20mg/ml was higher among those mainly using disposable (47.9%) compared with pod (16.3%) or refillable (11.5%) devices; never smokers (36.0%), current smokers (28.8%), or recent (<1y) ex-smokers (27.4%), compared with long-term ex-smokers (13.9%); and younger (16-24y; 44.2%) compared with older (≥25y; range 9.4-25.1%) age groups. There were no notable differences across other subgroups of interest.
Conclusions Use of high-strength nicotine e-liquids in England has increased sharply in recent years. Most adult vapers in Great Britain use e-cigarettes that contain nicotine but different subgroups use different strengths: they tend to be higher among those who mainly use disposable devices, those aged 16-24y, and lower among long-term ex-smokers.
Competing Interest Statement
JB has received unrestricted research funding from Pfizer and J&J, who manufacture smoking cessation medications. LS has received honoraria for talks, unrestricted research grants and travel expenses to attend meetings and workshops from manufactures of smoking cessation medications (Pfizer; J&J), and has acted as paid reviewer for grant awarding bodies and as a paid consultant for health care companies. All authors declare that they have never had any financial links with tobacco companies, e-cigarette manufacturers, or their representatives.
Funding Statement
This work was supported by Cancer Research UK (PRCRPG-Nov21\100002).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the STS was granted originally by the UCL Ethics Committee (ID 0498/001). The data are not collected by UCL and are anonymised when received by UCL.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
